Our 2023 Partners
Bio-Phenomenex is a leading company in manufacturing reliable and
high-quality column chemistry and solid phase extraction consumables
to serve as control strategies for robust traditional and emerging
biotherapeutic analytical methods.
Boston Analytical is a cGMP compliant, FDA/DEA registered, ISO/IEC-17025:2005 certified analytical laboratory. We have the latest bioanalytical equipment and can help with peptide, protein, and oligonucleotide analysis and characterization under guidance documents such as ICH Q6B. Boston Analytical offers compendial methods as well as methods developed specific to your products. Boston Analytical offers compendial methods as well as methods developed specific to your products.
BSP Pharmaceuticals is a Contract Development and Manufacturing Organization fully dedicated to antineoplastic drugs, designed to handle the complexity of biopharmaceutical products and offering customized services to support its client from development to commercial manufacturing of injectables and oral formulations. BSP Pharmaceuticals is focused on innovative therapies such as Proteosome Inhibitors, Antibody Drug Conjugates (ADCs) , Liposomal formulations, handling the major platforms of ADC compounds currently in clinical and commercial phase.
With nearly three decades of experience in large molecule bioanalysis and characterization, our experts have considerable knowledge of the evolving regulatory framework across various regions and the scientific background of this product class. By bringing quality and safety to life, our scientists work with clients globally, helping them meet all regulatory expectations and specifications for successful drug substance and drug product release. For ADCs, we provide expertise in GLP/GMP laboratory testing, bioanalysis, characterization, purity and impurity profile, stability testing and comparability, and more – all delivered consistently with precision, pace, and passion, allowing you to power ahead safely.
LiVeritas Biosciences enables drug development leaders to meet accelerated timelines through our proprietary AI-powered mass spectrometry solutions for rapid drug quality testing.
Founded in 2021 as a tech-enabled service provider, LiVeritas has helped clients hasten their drug development from design to BLA submission by providing timely quality mass spec data and unique insights.
This year, we will launch our AI-powered drug quality integration platform, assisting our clients to rapidly advance drug candidates with the best chance for clinical success - a step closer to regulatory approval.